Production (Stage)
Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.34M | 1.14M | 1.05M | 1.14M | 1.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.77M | 1.86M | 1.92M | 2.52M | 3.76M |
| Operating Income | -3.77M | -1.86M | -1.92M | -2.52M | -3.76M |
| Income Before Tax | -2.41M | -782.80K | -2.06M | -2.65M | -3.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.41 | -0.78 | -2.06 | -2.65 | -3.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.41M | -782.80K | -2.06M | -2.65M | -3.89M |
| EBIT | -3.77M | -1.86M | -1.92M | -2.52M | -3.76M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.37 | -0.18 | -0.51 | -0.68 | -1.01 |
| Normalized Basic EPS | -0.23 | -0.11 | -0.32 | -0.43 | -0.63 |
| EPS Diluted | -0.38 | -0.18 | -0.51 | -0.69 | -1.01 |
| Normalized Diluted EPS | -0.23 | -0.11 | -0.32 | -0.43 | -0.63 |
| Average Basic Shares Outstanding | 22.14M | 19.57M | 17.25M | 16.54M | 15.85M |
| Average Diluted Shares Outstanding | 22.80M | 20.23M | 17.43M | 16.73M | 15.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |